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http://www.molecular-cancer.com/content/12/1/58SHORT COMMUNICATION Open AccessPseudomonas aeruginosa NfsB and nitro-CBI-DEI –
a promising enzyme/prodrug combination for
gene directed enzyme prodrug therapy
Laura K Green1, Sophie P Syddall2, Kendall M Carlin2, Glenn D Bell2, Christopher P Guise2,3, Alexandra M Mowday2,
Michael P Hay2,3, Jeffrey B Smaill2,3, Adam V Patterson2,3 and David F Ackerley1,3,4*Abstract
Background: The nitro-chloromethylbenzindoline prodrug nitro-CBI-DEI appears a promising candidate for the
anti-cancer strategy gene-directed enzyme prodrug therapy, based on its ability to be converted to a highly
cytotoxic cell-permeable derivative by the nitroreductase NfsB from Escherichia coli. However, relative to some other
nitroaromatic prodrugs, nitro-CBI-DEI is a poor substrate for E. coli NfsB. To address this limitation we evaluated
other nitroreductase candidates from E. coli and Pseudomonas aeruginosa.
Findings: Initial screens of candidate genes in the E. coli reporter strain SOS-R2 identified two additional
nitroreductases, E. coli NfsA and P. aeruginosa NfsB, as being more effective activators of nitro-CBI-DEI than E. coli
NfsB. In monolayer cytotoxicity assays, human colon carcinoma (HCT-116) cells transfected with P. aeruginosa NfsB
were >4.5-fold more sensitive to nitro-CBI-DEI than cells expressing either E. coli enzyme, and 23.5-fold more
sensitive than untransfected HCT-116. In three dimensional mixed cell cultures, not only were the P. aeruginosa NfsB
expressing cells 540-fold more sensitive to nitro-CBI-DEI than pure cultures of untransfected HCT-116, the activated
drug that they generated also displayed an unprecedented local bystander effect.
Conclusion: We posit that the discrepancy in the fold-sensitivity to nitro-CBI-DEI between the two and three
dimensional cytotoxicity assays stems from loss of activated drug into the media in the monolayer cultures. This
emphasises the importance of evaluating high-bystander GDEPT prodrugs in three dimensional models. The high
cytotoxicity and bystander effect exhibited by the NfsB_Pa/nitro-CBI-DEI combination suggest that further
preclinical development of this GDEPT pairing is warranted.
Keywords: Gene therapy, GDEPT, Nitroaromatic prodrug, Nitroreductase, Nitro-CBI-DEI, CB1954, SOS chromotest,
Bystander effectBackground
In gene-directed enzyme prodrug therapy (GDEPT)
tumour cells are sensitised, via selective transgene deliv-
ery and/or expression, to a systemically administered
prodrug. A key aspect of GDEPT is the bystander effect,
the ability of activated prodrugs to transport either pas-
sively or actively out of the cell of origin and into
neighbouring non-transfected cells, which provides an* Correspondence: david.ackerley@vuw.ac.nz
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reproduction in any medium, provided the orelegant solution to the unavoidable issue of low cell
transfection rates [1]. Studies employing prodrugs with
high bystander effects have demonstrated that significant
tumour reduction can occur when less than 0.1% of the
tumour population expresses the activating enzyme [2].
Bacterial type I nitroreductase enzymes, which catalyse
the simultaneous two-electron bioreductive activation of
nitroaromatic prodrug substrates, hold great potential
for GDEPT. To date, the majority of nitroreductase
GDEPT studies have focused on the prodrug CB1954 [5-
(aziridin-1-yl)-2,4-dinitrobenzamide] (Figure 1B, struc-
ture inset), which exhibits only a modest bystander effect
upon activation [3]. However, the intrinsically oxygentd. This is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and
iginal work is properly cited.
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http://www.molecular-cancer.com/content/12/1/58insensitive nature of the two-electron reduction mechan-
ism enables nitroaromatic prodrugs that were originally
designed to target tumour hypoxia (i.e. by exploiting the
oxygen-sensitive one-electron reduction mechanism of
endogenous human reductases), to potentially be re-
purposed for nitroreductase GDEPT [1]. The main class
of hypoxia-activated prodrugs to have been considered in


















































































































Figure 1 Fold-induction of SOS response in SOS-R2 strains over-expre
nitro-CBI-DEI. Mid-exponential phase cultures of each SOS-R2 sfiA:lacZ rep
expression vector pUCX or containing an empty pUCX plasmid control, we
B. 20 μM CB1954, after which relative induction of the SOS response in eac
described [8]. Data are the mean Miller units from three independent expe
deviation. The black dotted line indicates the basal SOS activity in the emp
Dunnett comparison of test to control.e.g. [4-6]; not only are these substantially more cytotoxic
and generally better tolerated than CB1954, they also typ-
ically exert a greater bystander effect [3,4,7].
Also promising for GDEPT are the nitro-
chloromethylbenzindolines (nitro-CBIs), originally designed
to be hypoxia-activated prodrugs [9] of amino analogues of
the cyclopropylindoline anti-tumour antibiotics, exempli-
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re incubated for 3 h in the presence of A. 5 μM nitro-CBI-DEI or
h strain was measured by β-galactosidase assay as previously
riments, each performed in duplicate; and error bars are ± 1 standard
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http://www.molecular-cancer.com/content/12/1/58shown that the Escherichia coli nitroreductase NfsB
(NfsB_Ec) can reduce nitro-CBIs in an oxygen-independent
fashion, generating highly cytotoxic metabolites that alkyl-
ate the N3 of adenine in the minor groove of DNA [12].
However, it was inferred that the lead nitro-CBI prodrug in
that study, nitro-CBI-5-[(dimethylamino)ethoxy]indole (ni-
tro-CBI-DEI; Figure 1A, structure inset) is a poor substrate
for NfsB_Ec relative to CB1954 or the DNBMs [12]. In this
work we sought to identify more active nitroreductases for
metabolism of nitro-CBI-DEI, reasoning that superior en-
zymes will be required to extend the therapeutic index of
nitro-CBI prodrugs in GDEPT.
Findings
To identify novel nitroreductase enzymes we previously
constructed an over-expression library of eleven candi-
date oxidoreductases from E. coli [13]. Here, preliminary
screens of this library indicated that in addition to
NfsB_Ec, E. coli NfsA (NfsA_Ec) was able to activate
nitro-CBI-DEI to a measurable extent (not shown). We
next tested an orthologous collection of oxidoreductase
enzymes from Pseudomonas aeruginosa (Table 1), which
we had independently assembled to investigate their
hypothesised role in reducing antioxidant quinones in
this bacterium (LK Green, AC la Flamme and DF
Ackerley, unpublished work). When NfsA_Ec, NfsB_Ec
and the P. aeruginosa enzymes were individually over-
expressed in the E. coli strain SOS-R2, which contains a
lacZ reporter gene under control of the SOS responsive
promoter sfiA [6], NfsA_Ec, NfsB_Ec, and NfsB_Pa allTable 1 Nitroreductase candidates evaluated in this study
Protein namea Gene locusb % identityc Accession no.d
NfsB_Pa PA5190 25 (NfsB_Ec) AAG08575.1
AzoR2_Pa PA1962 41 (AzoR_Ec) AAG05350.1
AzoR3_Pa PA3223 45 (AzoR_Ec) AAG06611.1
KefF_Pa PA4975 37 (KefF_Ec) AAG08360.1
MdaB_Pa PA2580 64 (MdaB_Ec) AAG05968.1
WrbA_Pa PA0949 39 (WrbA_Ec) AAG04338.1
YcaK1_Pa PA1225 33 (YcaK_Ec) AAG04614.1
YcaK2_Pa PA0853 27 (YcaK_Ec) AAG04242.1
YdjA_Pa PA3208 42 (YdjA_Ec) AAG06596.1
YieF_Pa PA1204 45 (YieF_Ec) AAG04593.1
NfsA_Ec - 100 (NfsA_Ec) BAA35562.1
NfsB_Ec - 100 (NfsB_Ec) AAC73679.1
aProtein nomenclature as assigned in this study, based on existing
nomenclature of closest E. coli orthologue, with the exception of AzoR2 and
AzoR3 named as per existing GenBank annotations. Suffix _Pa indicates host
of origin was P. aeruginosa PAO1; _Ec indicates E. coli W3110.
bGene locus ID for P. aeruginosa proteins, as assigned in Pseudomonas
Genome Database [14].
cPercentage amino acid identity shared with closest E. coli orthologue
(identified in parentheses).
dGenBank accession number for protein sequences.generated a powerful induction of the SOS (DNA dam-
age repair) response following challenge with 5 μM
nitro-CBI-DEI (Figure 1A). In contrast, only NfsA_Ec
and NfsB_Ec induced a substantial SOS response follow-
ing challenge with 20 μM CB1954 (Figure 1B).
To further distinguish the ability of NfsA_Ec, NfsB_Ec,
and NfsB_Pa to activate each prodrug we employed a
bacteria-delivered enzyme cytotoxicity assay, as previ-
ously described [8]. E. coli strains individually over-
expressing each nitroreductase or containing an empty
plasmid control were incubated in co-culture with a
monolayer of untransfected human colon carcinoma
(HCT-116) cells across a range of concentrations of
CB1954 (25–400 μM) or nitro-CBI-DEI (0.06-15 μM).
Consistent with the SOS assays, the two E. coli enzymes
were far more effective than NfsB_Pa in sensitizing HCT-
116 cells to CB1954 (Figure 2A); whereas NfsB_Pa
exhibited a significantly lower IC50 (the concentration of






















































Figure 2 Bacteria-delivered enzyme prodrug cytotoxicity assay.
Calculated IC50 of HCT-116 cells post-incubation with E. coli cells
(over-expressing either NfsA_Ec, NfsB_Ec, NfsB_Pa, or an empty
pUCX control) across a serial 2-fold dilution series of A. CB1954 (25
μM to 400 μM); or B. nitro-CBI-DEI (0.06 μM to 15 μM). Following 4 h
of incubation bacteria and prodrug were removed by PBS washes,
and surviving HCT-116 cells allowed to recover in fresh Dulbecco's
modified Eagle's medium supplemented with fetal calf serum,
10 mM HEPES and 100 μg/ml chloramphenicol, as described [8].
Percentage cell survival at each prodrug concentration was then
calculated relative to an unchallenged control by CellTiter 96®
AQueous One Solution Cell Proliferation Assay (Promega). Data are
the mean of three independent experiments, each performed in
duplicate; and error bars are ± 1 standard deviation. ** indicates
p < 0.005 and *** p < 0.001 by one-way ANOVA with Dunnett
comparison of test to control.
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http://www.molecular-cancer.com/content/12/1/58unchallenged control levels) with nitro-CBI-DEI than ei-
ther NfsA_Ec or NfsB_Ec (p ≤ 0.001; T-test) (Figure 2B).
We next created HCT-116 cell lines stably transfected
with NfsA_Ec, NfsB_Ec or NfsB_Pa, using the Gateway™
compatible expression plasmid F527-V5, which expresses
inserted genes from a constitutive human elongation
factor-1 alpha promoter (all details as per [13]). Functional
nitroreductase activity was confirmed qualitatively for all
three stably transfected cell lines, but not the parental
HCT-116 cells, using the bacterial nitroreductase specific
fluorogenic probe FSL81 as previously described [6]
(Figure 3). The sensitivity of each cell line towards
nitro-CBI-DEI was then evaluated using an in vitro
proliferation assay as described [3]. Briefly, replicate
monolayers (n = 3) of NfsA_Ec, NfsB_Ec, NfsB_Pa or non-
transfected HCT-116 cells were exposed to a range of
concentrations of nitro-CBI-DEI (dilution series from 15.2
pM to 0.3 μM) for 18 h. Cells were washed free of drug
and incubated for a further 4 days, after which wells were
stained with sulforhodamine B to detect protein as a
measure of cell proliferation. Consistent with the results
of the bacteria-delivered cytotoxicity assays, the stably
transfected NfsB_Pa cell line (IC50 = 2.0 ± 0.4 nM) wasFigure 3 Confirmation of functional nitroreductase expression in HCT
to a blue fluorescent product in HCT116 cells expressing nfsB_Pa, nfsA_Ec o
plated at a density of 50,000 cells per well in a 24 well plate containing fre
was aspirated and replaced with fresh media containing 50 μM FSL81, follo
fluorescence mode (right; excitation 390/40 nm, emission 446/33 nm) takesignificantly more sensitive to nitro-CBI-DEI than either
the NfsA_Ec (IC50 = 24 ± 5 nM), NfsB_Ec (IC50 = 9.0 ± 1.2
nM) or parental HCT-116 (IC50 = 47 ± 9.2 nM) cell lines
(p ≤ 0.003; T-test). The 5.2-fold differential between WT
and NfsB_Ec cells is consistent with the 4.6-fold differen-
tial reported previously for these cell lines [12] but is con-
siderably smaller than the 23.5-fold differential observed
here between WTand NfsB_Pa cells.
The role of NfsB_Ec in the activation of nitro-CBI-DEI
has previously been explored in a three dimensional cell
culture model, in which expression of NfsB_Ec sensitised
HCT-116 cells to nitro-CBI-DEI by a factor of 12-fold,
and there was evidence of a substantial bystander effect
for the activated metabolite(s) [12]. Having shown
NfsB_Pa to be superior to NfsB_Ec at activating nitro-
CBI-DEI in cell monolayers, we next sought to quantify
the ability of a minority of NfsB_Pa transfected ‘activa-
tor’ cells to kill untransfected HCT-116 ‘target’ cells in
three dimensional (3D) co-cultures [3], via the bystander
effect of activated nitro-CBI-DEI metabolites (Figure 4).
Sensitivity to nitro-CBI-DEI was calculated using a post-
exposure clonogenic endpoint [3], where the C10 value
represents the concentration of nitro-CBI-DEI that-116 cells using the fluorogenic probe FSL81. FSL81 is metabolised
r nfsB_Ec, but not in untransfected wild type (WT) cells. Cells were
sh αMEM media amended with 5% fetal calf serum. After 3 h media
wed by incubation for a further 2 h. Images are relief phase (left) or
n using an EVOS® Floid® Cell Imaging Station (Invitrogen, Carlsbad, CA).
Green et al. Molecular Cancer 2013, 12:58 Page 5 of 6
http://www.molecular-cancer.com/content/12/1/58yields one log of cell kill. In cultures of 100% target cells,
the C10 value was 52.3 μM (Figure 4). In contrast, in co-
cultures of target cells and a minority (5.8% ± 3.2%) of
NfsB_Pa-transfected activator cells, the activator cells
were 540-fold more sensitive to nitro-CBI-DEI, with a
C10 value of 0.097 μM (Figure 4). The target cells in this
3D co-culture were nearly as sensitive as the activators,
their C10 value of 0.19 μM indicating an almost perfectly
uniform transfer of toxicity (Figure 4). The overall by-
stander effect efficiency (BEE) was calculated to be 89%;
this strikingly efficient transfer of cytotoxicity compares
to previously measured BEEs of 13% for CB1954, and
48% for the lipophilic DNBM prodrug SN27686 (using
NfsB_Ec expressing activator cells) [4]. The BEE is a
measure of the extent to which activator cells cause
the dose response curve for co-cultured target cells to
shift toward the activator dose response curve; and is
calculated according to the formula (LogC10T-
LogC10TC)/(LogC10T-LogC10AC), where C10T is the
C10 value for a pure culture of target cells, C10TC is the
C10 value for target cells in co-culture with activators, and
C10AC is the C10 value for those activator cells [4]. It is im-
portant to acknowledge that the quoted BEEs for CB1954
and SN27686 were measured using only a 1% activator cell
population [4]. However, in another study that used a 50%
activator cell population [7], the shift in dose responseFigure 4 Bystander effect from metabolic activation of nitro-CBI-DEI i
generated using cells from three-dimensional multicellular layers exposed t
hypoxia/necrosis in cells at the centre together with confounding activatio
100% HCT116 wild type ‘target’ cells or cocultures of target cells in the pre
3.2%). To establish the C10 values of target and activator cells in co-culture,
amended with 3 μM puromycin). The target cell population was calculated
(colonies counted on selective plates) from the total cell population (colon
sets from two independent experiments with overlapping data points; and
log of cell kill. The C10 values in targets alone (T), targets in co-culture (TC)curve for the co-cultured target cells was still less substan-
tial with any of the five prodrugs examined (CB1954,
RSU-1069, triapazamine, or the DNBMs SN23862 or
SN23816) than with nitro-CBI-DEI and the 5.8% acti-
vator cell population in our study.
The disparity between killing of NfsB_Pa transfected
HCT-116 cells due to nitro-CBI-DEI activation in the
in vitro IC50 proliferation assay and the 3D mixed cell
cultures highlights the importance of evaluating poten-
tial GDEPT enzyme-prodrug partnerships in a 3D by-
stander model, as low cell density may dramatically
underestimate cytotoxic potential. We surmise that the
cytotoxic potential of nitro-CBI-DEI may be dramatically
underestimated in low cell density proliferation assays
due to washout and loss in the media, as suggested for
other high-bystander prodrugs [3].
The unprecedented level of bystander killing, coupled
with the substantial superiority of NfsB_Pa over NfsB_Ec
in sensitising 3D cultures of nitroreductase-expressing
HCT-116 cells to nitro-CBI-DEI, suggests that the
NfsB_Pa/nitro-CBI-DEI combination is worthy of fur-
ther evaluation in preclinical GDEPT models. Should it
prove necessary to further enhance enzyme activity via
directed evolution or targeted mutagenesis studies, our
demonstration that nitro-CBI-DEI induces the E. coli
SOS response upon activation indicates that it should ben multicellular layer cultures. Clonogenic survival curves were
o nitro-CBI-DEI under hyperoxic conditions (95% O2; used to avoid
n of nitro-CBI-DEI due to hypoxia). Multicellular layers consisted of
sence of a small percentage of HCT116 NfsB_Pa ‘activator’ cells (5.8 ±
cells were plated in both non-selective and selective media (the latter
by subtracting the number of puromycin resistant activator cells
ies counted on non-selective plates). Points are the combined data
error bars are ± 1 standard deviation. The dashed line represents one
or activators in co-culture (AC) were interpolated.
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http://www.molecular-cancer.com/content/12/1/58possible to recover improved NfsB_Pa variants by SOS
screening, as previously used to generate superior CB1954
activating variants of the Vibrio fischeri nitroreductase
FRaseI [8].
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